Johnson & Johnson (NYSE:JNJ) Price Target Cut to $280.00 by Analysts at Royal Bank Of Canada

Johnson & Johnson (NYSE:JNJ) had its target price dropped by research analysts at Royal Bank Of Canada from $290.00 to $280.00 in a note issued to investors on Wednesday, Benzinga reports. The brokerage presently has an “outperform” rating on the stock. Royal Bank Of Canada’s price target would suggest a potential upside of 11.65% from the company’s previous close.

A number of other research firms also recently commented on JNJ. Wells Fargo & Company restated an “overweight” rating and set a $275.00 price target on shares of Johnson & Johnson in a research report on Wednesday. Stifel Nicolaus set a $260.00 price objective on shares of Johnson & Johnson in a report on Wednesday, July 15th. HSBC raised their price objective on shares of Johnson & Johnson from $290.00 to $320.00 and gave the company a “buy” rating in a research note on Thursday, September 10th. Raymond James Financial set a $280.00 target price on Johnson & Johnson in a report on Monday, August 3rd. Finally, Sanford C. Bernstein restated a “market perform” rating on shares of Johnson & Johnson in a research report on Wednesday. One equities research analyst has rated the stock with a Strong Buy rating, eighteen have given a Buy rating and six have given a Hold rating to the stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $273.30.

Johnson & Johnson Price Performance

Shares of JNJ opened at $250.78 on Wednesday. The firm has a market capitalization of $604.35 billion, a price-to-earnings ratio of 28.96, a price-to-earnings-growth ratio of 2.70 and a beta of 0.21. The company has a debt-to-equity ratio of 0.44, a quick ratio of 0.81 and a current ratio of 1.09. Johnson & Johnson has a one year low of $184.66 and a one year high of $281.07. The stock’s fifty day moving average is $265.89 and its 200-day moving average is $249.37.

Johnson & Johnson (NYSE:JNJ) last posted its quarterly earnings data on Tuesday, October 13th. The company reported $2.59 earnings per share for the quarter, topping the consensus estimate of $2.53 by $0.06. The business had revenue of $25.40 billion during the quarter, compared to the consensus estimate of $25.38 billion. Johnson & Johnson had a net margin of 21.48% and a return on equity of 32.42%. The company’s quarterly revenue was up 5.9% compared to the same quarter last year. During the same quarter in the prior year, the company posted $2.80 earnings per share. Johnson & Johnson has set its FY 2026 guidance at 11.050-11.150 EPS. Equities analysts anticipate that Johnson & Johnson will post 11.09 EPS for the current year.

Insider Buying and Selling at Johnson & Johnson

In other news, EVP Jennifer L. Taubert sold 15,000 shares of Johnson & Johnson stock in a transaction that occurred on Monday, August 17th. The shares were sold at an average price of $263.36, for a total value of $3,950,400.00. Following the transaction, the executive vice president owned 194,451 shares of the company’s stock, valued at $51,210,615.36. The trade was a 7.16% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this link. Also, EVP Timothy Schmid sold 33,597 shares of the business’s stock in a transaction that occurred on Wednesday, September 2nd. The stock was sold at an average price of $274.74, for a total transaction of $9,230,439.78. Following the completion of the sale, the executive vice president owned 25,447 shares in the company, valued at $6,991,308.78. The trade was a 56.90% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 87,569 shares of company stock valued at $23,064,544 over the last 90 days. Insiders own 0.16% of the company’s stock.

Institutional Trading of Johnson & Johnson

Large investors have recently added to or reduced their stakes in the business. Auto Owners Insurance Co grew its position in shares of Johnson & Johnson by 22,225.6% during the 4th quarter. Auto Owners Insurance Co now owns 69,419,308 shares of the company’s stock worth $1,436,633,000 after purchasing an additional 69,108,368 shares in the last quarter. Wellington Management Group LLP raised its position in shares of Johnson & Johnson by 12.5% in the second quarter. Wellington Management Group LLP now owns 22,588,696 shares of the company’s stock valued at $5,736,851,000 after buying an additional 2,513,321 shares in the last quarter. Deutsche Bank AG boosted its stake in shares of Johnson & Johnson by 8.5% in the second quarter. Deutsche Bank AG now owns 15,661,323 shares of the company’s stock valued at $3,977,506,000 after buying an additional 1,225,676 shares during the period. Amundi grew its position in Johnson & Johnson by 17.5% during the first quarter. Amundi now owns 13,406,820 shares of the company’s stock worth $3,277,163,000 after buying an additional 2,001,139 shares in the last quarter. Finally, Janus Henderson Group PLC grew its position in Johnson & Johnson by 1.9% during the first quarter. Janus Henderson Group PLC now owns 7,872,478 shares of the company’s stock worth $1,924,323,000 after buying an additional 148,497 shares in the last quarter. 69.55% of the stock is currently owned by institutional investors.

Key Johnson & Johnson News

Here are the key news stories impacting Johnson & Johnson this week:

• Positive Sentiment: Johnson & Johnson reported third-quarter adjusted EPS of $2.59, ahead of the $2.53 consensus, while revenue increased 5.9% year over year to $25.4 billion, roughly matching expectations. Johnson & Johnson earnings results
• Positive Sentiment: Management raised its 2026 outlook to $101.0 billion-$101.4 billion in revenue and $11.05-$11.15 in adjusted EPS. Innovative Medicine was the key growth driver, including strong oncology results and rapid TREMFYA growth. Johnson & Johnson Q3 results and guidance
• Positive Sentiment: The company declared a quarterly dividend of $1.34 per share, or $5.36 annualized, reinforcing JNJ’s appeal as an income-oriented healthcare stock. Johnson & Johnson quarterly dividend
• Neutral Sentiment: Johnson & Johnson is considering a mid-2027 spinoff of its hips-and-knees orthopedic business. A separation could sharpen the company’s portfolio focus, but it also highlights ongoing challenges in the medical-device operation. J&J hips-and-knees business spinoff
• Negative Sentiment: MedTech grew only about 2.5% operationally and missed expectations, with weakness in surgery and cardiovascular products, particularly outside the United States. Investors viewed the shortfall as more important than the pharmaceutical strength. Johnson & Johnson MedTech weakness
• Negative Sentiment: Reported profit plunged because of one-time costs tied largely to the proposed talc litigation resolution, as well as acquisitions and collaborations. GAAP EPS fell to $0.09 from $2.80 a year earlier, overshadowing the adjusted earnings beat. Johnson & Johnson quarterly report analysis
• Negative Sentiment: The guidance increase was modest relative to elevated investor expectations, while Erste Group reduced its FY2027 EPS estimate to $12.65 from $12.83, adding to concerns about future earnings growth.

Johnson & Johnson Company Profile

Johnson & Johnson (NYSE: JNJ) is a global healthcare company that develops, manufactures and markets products through two primary business segments: Innovative Medicine and MedTech. Its operations serve patients, healthcare professionals and consumers in markets around the world.

The Innovative Medicine segment focuses on prescription medicines in areas including immunology, oncology, neuroscience, cardiovascular and metabolic disease, infectious diseases, and pulmonary hypertension.